FilingSEC EDGAR424B5
Kazia Therapeutics announces public offering and reports positive clinical data
· SEC accepted
StagePhase 1b
Filing content
The company reported a 100% clinical benefit rate in its Phase 1b trial for paxalisib and is conducting a public offering of ADSs and warrants to fund clinical development.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…